Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
ArchiMed sells Diesse to Fremman Capital, delivering 4.6x return to shareholders
ArchiMed exited its investment in Diesse through a sale to private equity firm Fremman Capital, generating a 4.6x return for shareholders. The transaction concludes a five-year partnership in which ArchiMed helped transform Diesse into a leading clinical diagnostics...
Ares and Carlyle invest €800m in Your.World to fuel M&A growth
Ares Management Credit Funds and Carlyle Inc. have committed €800m in preferred equity to Your.World, a European leader in online solutions, supporting its expansion and acquisition strategy. Founded in 2016 by Strikwerda Investments, Your.World specializes in web...
KKR expands stake in Henry Schein, secures board seats to influence strategy
KKR strengthened its position in Henry Schein, increasing its stake to 12% with the option to acquire an additional 2.9% in the future. As part of the deal, Henry Schein has granted KKR two board seats. This reinforces the private equity firm's influence over the...